

# Arielle Mendel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2266311/publications.pdf>

Version: 2024-02-01

15  
papers

157  
citations

1162367

8  
h-index

1281420

11  
g-index

15  
all docs

15  
docs citations

15  
times ranked

270  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.1-2.	0.5	31
2	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. <i>Journal of Rheumatology</i> , 2021, 48, 555-566.	1.0	27
3	Hydroxychloroquine shortages during the COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e31-e31.	0.5	26
4	COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. <i>Journal of Rheumatology</i> , 2022, 49, 523-530.	1.0	18
5	Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. <i>Rheumatology</i> , 2019, 58, 2333-2335.	0.9	14
6	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
7	Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: Data from the Toronto CanVasc cohort. <i>Joint Bone Spine</i> , 2020, 87, 221-224.	0.8	12
8	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	0.9	8
9	Best Practices for Virtual Care: A Consensus Statement From the Canadian Rheumatology Association. <i>Journal of Rheumatology</i> , 2022, 49, 408-418.	1.0	6
10	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 119-124.	0.4	2
11	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 119-124.	0.4	1
12	An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e612-e615.	0.5	0
13	Facteurs prédictifs d'événements cardiovasculaires mortels et non mortels dans la vascularite à ANCA: données de la cohorte Toronto CanVasc. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 279-283.	0.0	0
14	Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210537.	1.0	0
15	More than a Hundred Days War™: Persistent SARS-CoV-2 infection in a patient with ANCA-associated vasculitis. <i>Jammi</i> , 0, , .	0.3	0